Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 55-year-old woman with a mechanical mitral valve presents to the outpatient clinic reporting two days of dysuria, urinary frequency, and suprapubic discomfort. She is currently on a stable regimen of warfarin. Her most recent international normalized ratio (INR) from two weeks ago was 3.1 (target range 2.5 to 3.5). A point-of-care urinalysis is positive for leukocyte esterase and nitrites. The physician diagnoses an uncomplicated lower urinary tract infection and prescribes a 3-day course of trimethoprim-sulfamethoxazole. Which of the following is the most appropriate next step in the management of this patient's anticoagulation therapy?

  1. Empirically reduce the warfarin dose and measure the international normalized ratio in 3 to 5 daysAnswer
  2. B
    Maintain the current warfarin dosage and measure the international normalized ratio upon completion of the antibiotic course
  3. C
    Discontinue the warfarin and initiate rivaroxaban for the duration of the antibiotic therapy
  4. D
    Administer prophylactic oral phytonadione prior to initiating the antibiotic
  5. E
    Check a baseline activated partial thromboplastin time prior to antibiotic initiation

Answer

Empirically reduce the warfarin dose and measure the international normalized ratio in 3 to 5 days
The correct approach involves recognizing that trimethoprim-sulfamethoxazole (TMP-SMX) is a strong inhibitor of CYP2C9, the primary enzyme responsible for clearing the more potent S-enantiomer of warfarin. When these two drugs are co-administered, warfarin levels rise significantly, leading to a supratherapeutic INR and an increased risk of bleeding. The standard of care for monitoring and treatment evaluation in this scenario is to preemptively reduce the warfarin dose by 25% to 50% and closely monitor the INR by rechecking it within 3 to 5 days. This proactive strategy maintains the patient within the therapeutic window safely.

Step-by-Step Solution

1
Identify the pharmacokinetic interaction between the prescribed medications.
Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 2C9 enzyme, which metabolizes the active S-enantiomer of warfarin.
Recognizing drug-drug interactions is critical before starting new therapies in patients on narrow-therapeutic-index medications like warfarin.
2
Determine the necessary clinical intervention to mitigate risk.
The warfarin dose must be preemptively reduced (typically by 25% to 50%) to account for the decreased clearance.
Waiting for the INR to rise before intervening exposes the patient to an unacceptable risk of hemorrhage.
3
Establish the appropriate timeline for laboratory monitoring.
The INR should be rechecked in 3 to 5 days.
It takes several days for the altered metabolism to fully reflect on the INR, making a 3 to 5 day window ideal for catching early fluctuations.

Key Concept

Pharmacokinetic interactions of warfarin and proactive laboratory monitoring
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic